The coming glut? Cancer cell therapy trials are booming as China rivals US on new projects
The Cancer Research Institute has been keeping a careful eye on cancer R&D as new money continues to pour into the field from all directions. Today, in the lead up to ASCO this weekend, they’ve updated their work on cancer cell therapies — and as you might expect there’s plenty of signs that things are continuing to heat up.
The top highlights from the new report in Nature Reviews Drug Discovery by Jun Tang and colleagues
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.